10 Best Growth Stocks Under $20 to Buy

8. Monte Rosa Therapeutics Inc. (NASDAQ:GLUE)

Number of Hedge Fund Holders: 35

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) is one of the best growth stocks under $20 to buy. On May 7, Monte Rosa reported progress across its clinical-stage pipeline, with three programs advancing toward Phase 2 studies. MRT-8102, an NEK7-directed molecular glue degrader/MGD for inflammatory diseases, showed significant CRP reductions in early trials. The company plans to initiate multiple Phase 2 studies for MRT-8102 starting in H2 2026, targeting cardiovascular risk, gout, and hidradenitis suppurativa.

The company’s VAV1-directed MGD, MRT-6160, is progressing toward Phase 2 studies for immune-mediated diseases in collaboration with Novartis. Additionally, the GSPT1-directed MRT-2359 demonstrated encouraging efficacy in metastatic castration-resistant prostate cancer/mCRPC patients with androgen receptor/AR mutations, with a new Phase 2 study in combination with apalutamide planned for Q3 2026.

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) remains in a solid financial position, reporting $671 million in cash and equivalents, which is expected to support operations into 2029. Beyond its clinical assets, the company is advancing preclinical programs, including a cyclin E1-directed MGD for solid tumors, with an IND application expected in H2 2026.

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) is a Massachusetts-based clinical-stage biotechnology company developing novel small-molecule precision medicines. Incepted in 2019, the company maintains a strategic partnership and licensing agreement with F. Hoffmann-La Roche Ltd.

1281292 - 11759070 - 1